MET and cancer: Considering the effects of c-Met on cancer progression, several small molecule inhibitors have been pursued by pharmaceutical companies and researchers9–11, these include Crizotinib (Launched, 2011), Cabozantinib (Launched, 2012), Capmatinib (Launched, 2020), Savolitinib (Launched, 2021), Merestinib (Phase II) and so on (Figure 1).12–14